Open an account

Armata Pharmaceuticals

ARMP · NYSE American

$3.20+$0.13 (+4.23%)TodayMarket closed ·
Prev close $3.07

About ARMP

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, which focuses on the development of bacteriophage therapeutics for the treatment of drug-resistant bacterial infections. The company is headquartered in Los Angeles, California and currently employs 61 full-time employees. The firm is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. The company is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Employees
61
Headquarters
Los Angeles, California
Listed
May 20, 1994
Sector
Health Care
Industry
Biotechnology
Website
armatapharma.com

ARMP key statistics

Market cap
118.98M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
118.15K
Volume
87.39K
Open price
$3.14
High today
$3.41
Low today
$3.11
52 Week high
$16.34
52 Week low
$2.75

Armata Pharmaceuticals (ARMP) at a glance

As of Oct 20, 2026, Armata Pharmaceuticals (ARMP) shares are priced at $3.20, giving the company a market cap of 118.98M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.11 and $3.41. The current price is 2.9% above the day's low and 6.2% below its high.

Volume so far is 87.39K shares, below the average of 118.15K shares a day.

Over the past year Armata Pharmaceuticals has ranged from $2.75 to $16.34, and now sits 3% of the way up that range.

Armata Pharmaceuticals met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.27 per share against an estimate of -$0.4539.

The average analyst price target is $17.85, 457.8% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $17.85
Low
$15.15
Now
$3.20
High
$21.00

ARMP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 64.0% on average.

  1. Q3 FY24: reported -$0.15 per share against an estimate of -$0.2856
  2. Q4 FY24: reported $0.07 per share against an estimate of -$0.357
  3. Q1 FY25: reported -$0.20 per share against an estimate of -$0.3876
  4. Q2 FY25: reported -$0.45 per share against an estimate of -$0.3978
  5. Q3 FY25: reported -$0.74 per share against an estimate of -$0.4284
  6. Q4 FY25: reported -$3.27 per share against an estimate of -$0.2856
  7. Q1 FY26: reported -$3.16 per share against an estimate of -$0.3876
  8. Q2 FY26: reported -$0.27 per share against an estimate of -$0.4539

ARMP news

  • Press releasePRNewswire

    Armata Pharmaceuticals Strengthens Intellectual Property Portfolio with Two Recent Patent Issuances in the United States

  • Vandana Singh

    Armata Pharmaceuticals Stock Slides after Pentagon Funding Fuels Phase 3 Push for Anti-Bacterial Program

  • Press releasePRNewswire

    Armata Pharmaceuticals Receives $3.7 Million in Additional Non-Dilutive Funding from U.S. Department of War to Support Advancement of AP-SA02 Phase 3 Development

  • Press releasePRNewswire

    Armata Pharmaceuticals to Present Data at ISSSI 2026 Showing Defined Genetic Diversity in AP-SA02 May Enhance Killing of Certain Staphylococcus aureus Clinical Isolates

  • Press releasePRNewswire

    Armata Pharmaceuticals Receives U.S. FDA Breakthrough Therapy Designation for AP-SA02

  • Press releasePRNewswire

    Armata Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

  • Press releasePRNewswire

    Armata Pharmaceuticals Announces New Publication That Advances Understanding of Phage Biology to Support Development of Next-Generation Antibacterials

  • Press releasePRNewswire

    Armata Pharmaceuticals Announces Financial Results for the Second Quarter 2026 and Provides a Corporate Update

Similar companies

Companies in the same industry as Armata Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.